Sun Pharma Advanced Research Company Limited (NSE:SPARC)

Market Cap	62.67B +46.4%
Revenue (ttm)	19.09B +2,856.0%
Net Income	15.84B
EPS	48.80
Shares Out	324.52M
PE Ratio	4.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	469,488
Open	197.00
Previous Close	196.79
Day's Range	191.25 - 201.39
52-Week Range	108.00 - 289.00
Beta	0.65
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 2, 2026

About NSE:SPARC

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Ad...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 279
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SPARC

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 8, 2026

Data Sources Report a data error